Polyvascular

Executive Summary

Polyvascular is a San Diego-based private medical device company developing innovative polymer-based transcatheter heart valves designed specifically for children with congenital heart defects. Founded in 2018, the company aims to address the critical unmet need for durable, size-adaptable valves that can grow with the patient, thereby reducing the number of repeated open-heart surgeries required over a lifetime. Unlike current solutions using animal tissue or human donors, Polyvascular's polymer valves are designed to be biocompatible, non-thrombogenic, and capable of being delivered minimally invasively. The technology has the potential to transform pediatric cardiac care by offering a lifelong solution that adapts to a child's growth, improving outcomes and quality of life. While the company is still in early stages with no disclosed funding or clinical data, its novel approach targets a significant niche in the cardiovascular device market.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial initiation40% success
• Q3 2026Series A funding round closure60% success
• Q2 2026Preclinical study results publication70% success